BIOCON Financial Statement Analysis
|
||
|
The Revenues of BIOCON have increased by 10.91% YoY .
The Earnings Per Share (EPS) of BIOCON has decreased by -71.80 % YoY. |
||
BIOCON Last 5 Annual Financial Results
[BOM: 532523|NSE : BIOCON]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹16,927 Cr | ₹15,262 Cr | ₹14,756 Cr | ₹11,174 Cr | ₹8,184 Cr |
| Expenses | ₹13,585 Cr | ₹12,243 Cr | ₹11,559 Cr | ₹9,055 Cr | ₹6,691 Cr |
| Operating Profit (Excl OI) | ₹3,342 Cr | ₹3,019 Cr | ₹3,197 Cr | ₹2,120 Cr | ₹1,493 Cr |
| Other Income | ₹456 Cr | ₹1,356 Cr | ₹968 Cr | ₹768 Cr | ₹690 Cr |
| Interest | ₹990 Cr | ₹897 Cr | ₹974 Cr | ₹419 Cr | ₹68 Cr |
| Depreciation | ₹1,957 Cr | ₹1,687 Cr | ₹1,569 Cr | ₹1,113 Cr | ₹814 Cr |
| Profit Before Tax | ₹448 Cr | ₹1,887 Cr | ₹1,525 Cr | ₹897 Cr | ₹983 Cr |
| Profit After Tax | ₹369 Cr | ₹1,429 Cr | ₹1,298 Cr | ₹643 Cr | ₹772 Cr |
| Consolidated Net Profit | ₹386 Cr | ₹1,013 Cr | ₹1,023 Cr | ₹463 Cr | ₹648 Cr |
| Earnings Per Share (Rs) | ₹2.38 | ₹8.44 | ₹8.52 | ₹3.85 | ₹5.40 |
| PAT Margin (%) | 2.17 | 9.32 | 8.69 | 5.70 | 9.40 |
| ROE(%) | 1.35 | 7.03 | 7.00 | 4.98 | 9.83 |
| ROCE(%) | 3.26 | 7.43 | 7.03 | 5.37 | 8.30 |
| Total Debt/Equity(x) | 0.44 | 0.84 | 0.81 | 1.01 | 0.60 |
Key Financials |
||
| Market Cap | : | ₹ 68,936.3 Cr |
| Revenue (TTM) | : | ₹ 16,927.0 Cr |
| Net Profit(TTM) | : | ₹ 368.8 Cr |
| EPS (TTM) | : | ₹ 2.3 |
| P/E (TTM) | : | 186.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BIOCON | -2.2% | -0.8% | 8% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.4% | 2.4% | 17.1% |
| DIVIS LABORATORIES | 12.2% | 23.1% | 21.7% |
| TORRENT PHARMACEUTICALS | 2.4% | 5.3% | 41.7% |
| CIPLA | 1.7% | 0.7% | -3.8% |
| DR REDDYS LABORATORIES | 3% | -14.9% | -10.2% |
| MANKIND PHARMA | -5.5% | -2.2% | -5.1% |
| LUPIN | -0.8% | -4% | 23.7% |
| ZYDUS LIFESCIENCES | 1.5% | -2.2% | 15.3% |
BIOCON Revenues
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | 10.91 % |
| 5 Yr CAGR | 19.92 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹16,927 Cr | 10.91 | |
| Mar2025 | ₹15,262 Cr | 3.43 | |
| Mar2024 | ₹14,756 Cr | 32.05 | |
| Mar2023 | ₹11,174 Cr | 36.54 | |
| Mar2022 | ₹8,184 Cr | - | |
BIOCON Operating Profit
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | 10.70 % |
| 5 Yr CAGR | 22.32 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹3,342 Cr | 10.70 | |
| Mar2025 | ₹3,019 Cr | -5.57 | |
| Mar2024 | ₹3,197 Cr | 50.82 | |
| Mar2023 | ₹2,120 Cr | 42.00 | |
| Mar2022 | ₹1,493 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -0.20 % |
| 5 Yr CAGR | 2.00 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 19.74% | -0.20 | |
| Mar2025 | 19.78% | -8.68 | |
| Mar2024 | 21.66% | 14.18 | |
| Mar2023 | 18.97% | 4.00 | |
| Mar2022 | 18.24% | - | |
BIOCON Profit After Tax
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | -61.95 % |
| 5 Yr CAGR | -12.18 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹386 Cr | -61.95 | |
| Mar2025 | ₹1,013 Cr | -0.90 | |
| Mar2024 | ₹1,023 Cr | 120.99 | |
| Mar2023 | ₹463 Cr | -28.64 | |
| Mar2022 | ₹648 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -76.72 % |
| 5 Yr CAGR | -30.68 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 2.17 % | -76.72 | |
| Mar2025 | 9.32 % | 7.25 | |
| Mar2024 | 8.69 % | 52.46 | |
| Mar2023 | 5.7 % | -39.36 | |
| Mar2022 | 9.4 % | - | |
BIOCON Earnings Per Share (EPS)
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | -71.80 % |
| 5 Yr CAGR | -18.52 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹2.38 | -71.80 | |
| Mar2025 | ₹8.44 | -0.94 | |
| Mar2024 | ₹8.52 | 121.30 | |
| Mar2023 | ₹3.85 | -28.70 | |
| Mar2022 | ₹5.40 | - | |
BIOCON Return on Capital Employed (ROCE)
[BOM: 532523|NSE : BIOCON]
| Y-o-Y | -56.12 % |
| 5 Yr CAGR | -20.83 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 3.26% | -56.12 | |
| Mar2025 | 7.43% | 5.69 | |
| Mar2024 | 7.03% | 30.91 | |
| Mar2023 | 5.37% | -35.30 | |
| Mar2022 | 8.3% | - | |
BIOCON Share Price vs Sensex
| Current Share Price | : | ₹423.0 |
| Current MarketCap | : | ₹ 68,936.3 Cr |
| Updated EOD on | : | Aug 03,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BIOCON | -2.2% |
-0.8% |
8% |
| SENSEX | 2.4% |
1.5% |
-4.3% |
BIOCON related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 200 | 2.2% | 1.9% | 0.9% |
| BSE 250 LARGEMIDCAP INDEX | 2.2% | 1.8% | 1.1% |
| BSE 500 | 2.2% | 1.7% | 1.2% |
| BSE 200 EQUAL WEIGHT | 2.1% | 2.6% | 6.3% |
| BSE 1000 | 2.1% | 1.6% | 1.4% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY100 ENHANCED ESG | 3.8% | 4.9% | 4.4% |
| NIFTY100 ESG | 3.8% | 4.9% | 4.4% |
| NIFTY100 ESG SECTOR LEADERS | 3.2% | 2.8% | -0.9% |
| NIFTY 200 | 3% | 2.5% | 2.1% |
| NIFTY 500 | 2.8% | 2.3% | 2.2% |
You may also like the below Video Courses
FAQ about BIOCON Financials
How the annual revenues of BIOCON have changed ?
The Revenues of BIOCON have increased by 10.91% YoY .
How the Earnings per Share (EPS) of BIOCON have changed?
The Earnings Per Share (EPS) of BIOCON has decreased by -71.80 % YoY .
Check out Intrinsic Value of Peers of BIOCON
Compare Stock Analytics of Peers of BIOCON
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
